IBB
HealthcareiShares Biotechnology ETF
iShares · Tracks NYSE Biotechnology Index · Inception Feb 5, 2001
Trailing returns
through Oct 23, 2026- 1 year
- +31.7%
- 3 year
- +22.9%
- annualized
- 5 year
- +5.9%
- annualized
Price return from month-end closes, distributions reinvested at month end. Excludes trading costs, bid-ask spreads and taxes. Past performance says nothing about future returns and is not part of the composite score — see the methodology for what the score does measure.
Composite score
Based on a 0.44% expense ratio.
Based on $11.20B in net assets.
Top-10 holdings represent 44.7% of net assets.
Healthcare base · ETF wrapper · 0.16% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.2).
Look through IBB, or compare the fee
Tool · Look-through
Underlying holdings, with other funds added
Add tickers and weights; N-PORT positions are summed across the basket.
Tool · Cost
Compare IBB's fee against another fund
Compounds the 0.44% expense ratio against a peer over decades.
Tool · Overlap
Compare IBB's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Healthcare funds.
Tool · TLH
Find a tax-loss harvesting partner for IBB
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Asset location for IBB across account types
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | Vertex Pharmaceuticals, Inc. | 8.08% |
| 2 | Amgen, Inc. | 7.83% |
| 3 | Gilead Sciences, Inc. | 6.84% |
| 4 | Regeneron Pharmaceuticals, Inc. | 4.91% |
| 5 | Argenx SE | 3.76% |
| 6 | Alnylam Pharmaceuticals, Inc. | 3.12% |
| 7 | Natera, Inc. | 2.89% |
| 8 | Revolution Medicines, Inc. | 2.78% |
| 9 | Biogen, Inc. | 2.47% |
| 10 | Illumina, Inc. | 2.07% |
Compare IBB with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IBB at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.